Fri. Aug 19th, 2022
Aspergillosis Market

DelveInsight’s “Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the seven major markets (7MM) (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The report also covers provides insights into the emerging drugs, current treatment practices, market share of the individual therapies, market drivers, barriers, unmet medical needs, current and forecasted market size from 2019 to 2032 segmented by 7MM. 

Cholestatic Pruritus Disease Overview

Cholestasis is defined as a decrease in bile flow due to the impaired secretion by hepatocytes or due to the obstruction of bile flow through intra-or extra-hepatic bile ducts. This impairment in bile secretion occurs at somewhere between the liver cells (which produce bile) and the duodenum (the first segment of the small intestine).

Furthermore, Pruritus is a distressing manifestation of both intrahepatic cholestasis and extrahepatic biliary obstruction. Intrahepatic cholestasis processes associated with pruritus include Primary Biliary Cirrhosis (PBC), and cholestasis of pregnancy (pruritus gravidarum), drug-induced cholestasis, and viral hepatitis. However, pruritus is also seen in extrahepatic cholestatic liver diseases such as primary sclerosing cholangitis (PSC), and cancer of the head of the pancreas. Historically, pruritus has been observed to accompany jaundice, but it is not uncommon to see pruritus as the first manifestation of cholestasis even before the onset of jaundice or other symptoms. There is considerable variation in the frequency and prevalence of pruritus in different cholestatic conditions.

Interestingly, for reasons that are currently unexplained, the severity of pruritus seen in cholestatic conditions has no relationship with the degree of severity of cholestasis, i.e. patients with similar severities of liver disease and cholestasis can have markedly different degrees of pruritus.

Cholestatic Pruritus Market Key Facts

  • As per the Royal College of Obstetricians and Gynaecologists, the United Kingdom, obstetric cholestasis is a multifactorial condition of pregnancy characterized by pruritus in the absence of a skin rash with abnormal liver function tests. In England, this condition affects nearly 1% of pregnancies in multiethnic populations.
  • A study conducted by Dull and Kremer (2020) titled “Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease”, suggests that patients with genetic biliary disorders such as BRIC or PFIC commonly suffer from the cholestatic itch. Chronic pruritus is characteristic for the immune-mediated cholestatic disorders PBC, PSC, and SSC, with a lifetime prevalence of up to 70–80%. These numbers were substantiated by a national cohort study from the UK, in which 73.5% of the patients experienced pruritus at some point during their disease, 34.5% reported on persistent pruritus, and 11.7% on severe pruritus. 
  • A 2015 study titled “Drug treatment of pruritus in liver diseases” by Hegade et al., suggests that there is considerable variation in the frequency and prevalence of pruritus in different cholestatic conditions. For instance, it is experienced by up to 80% of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and by 5–15% of patients with chronic hepatitis C at any time during the course of their disease. It is less common in patients with extrahepatic cholestatic pruritus, as in one series pruritus occurred in 17%

Cholestatic Pruritus Market

Cholestatic Pruritus Market Size is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to understand the historic, current, and forecasted Cholestatic Pruritus market size by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. 

The report gives a thorough detail of key trends, ongoing developments, and growth opportunities of each marketed and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders in the domain. 

Get the PDF Sample of the Report @

Cholestatic Pruritus Epidemiology

The epidemiology section covers insights into the historical and current Cholestatic Pruritus patient pool and forecasted trends for every seven major markets from 2019 to 2032. 

It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Cholestatic Pruritus Epidemiology Segmentation –

  • Total Prevalent Population of Cholestatic Pruritus
  • Gender-specific Prevalent Population of Cholestatic Pruritus
  • Severity-specific Prevalent Population of Cholestatic Pruritus
  • Diagnosed and Treatable Population of Cholestatic Pruritus

Discover more about the epidemiological segmentation @

Cholestatic Pruritus Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched in the market during the study period. The analysis covers the drug uptake; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Cholestatic Pruritus Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent development such as collaborations, acquisitions, and mergers, licensing patent details, and other information.

Cholestatic Pruritus Therapeutics Analysis

The Cholestatic Pruritus market dynamics is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period. 

Currently, several major pharma giants are thoroughly working toward the development of new treatment therapies, in order to provide better relief for the symptoms and hence improve the QoL of patients with Cholestasis. 

Some of the key companies in the Cholestatic Pruritus Market include:

  • GlaxoSmithKline 
  • Mirum Pharmaceuticals 
  • Albireo Pharma 
  • Intercept Pharmaceuticals
  • Cymabay Therapeutics 
  • Care Therapeutics 

And others.

Cholestatic Pruritus Therapies covered in the report include:

  • GSK2330672
  • Maralixibat
  • Odevixibat
  • Seladelpar
  • Korsuva

And many more. 

Get More Detailed Insights into the Emerging Therapies & Key Companies:-

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Cholestatic Pruritus Competitive Intelligence Analysis
  4. Cholestatic Pruritus Market Overview at a Glance
  5. Cholestatic Pruritus Disease Background and Overview
  6. Cholestatic Pruritus Patient Journey
  7. Cholestatic Pruritus Epidemiology and Patient Population
  8. Cholestatic Pruritus Treatment Algorithm, Current Treatment, and Medical Practices
  9. Cholestatic Pruritus Unmet Needs
  10. Key Endpoints of Cholestatic Pruritus Treatment
  11. Cholestatic Pruritus Marketed Products
  12. Cholestatic Pruritus Emerging Therapies
  13. Cholestatic Pruritus Seven Major Market Analysis
  14. Attribute Analysis
  15. Cholestatic Pruritus Market Outlook (7 major markets)
  16. Cholestatic Pruritus Access and Reimbursement Overview
  17. KOL Views on the Cholestatic Pruritus Market.
  18. Cholestatic Pruritus Market Drivers
  19. Cholestatic Pruritus Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Contact Info:
Shruti Thakur
Assistant Manager, Marketing & IB
Phone No: +91-9650213330
Email: [email protected]
Connect With Us: LinkedIn | Facebook | Twitter
For Latest Update: Healthcare Blog
Request for Sample Copy of the Report at:


Latest Reports By DelveInsight:

Cholestatic Pruritus Epidemiology Forecast

“Cholestatic Pruritus Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cholestatic Pruritus in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cholestatic Pruritus Pipeline Insights

“Cholestatic Pruritus Pipeline Insights” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cholestatic Pruritus market.

Other Trending Healthcare Reports by DelveInsight

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *